Relay Therapeutics, Inc. (RLAY)
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Relay Therapeutics, Inc.
NASDAQ:RLAYHealthcare · Biotechnology
-5.75%$18.35
AH$18.22-0.69%vs close
Mkt Cap$4.02B
Float157.61M
O/S219.14M
Vol
$ Vol
RVOL
Inst Own-
SI27.9%
Earnings
Dilution
Financials Summary
Revenue$15.36M
Net Income-$276.48M
Total Assets$621.33M
Free Cash Flow-$235.87M
Debt & Equity
Debt 5%
Equity 95%
Total Debt$32.46M
Total Equity$567.06M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in RLAY's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$621.33M
Liabilities$54.27M
Accounts Receivable$0
Accounts Payable$7.71M
Inventory$0
PP&E (Net)$41.72M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $15.36M | $10.01M | $25.55M | $1.38M | $3.03M | $82.65M | $0 | $0 |
| YoY Growth | 53.4% | -60.8% | 1749.8% | -54.4% | -96.3% | - | - | - |
| Cost of Revenue | $3.56M | $315.44M | $326.39M | $243M | $169.39M | $3.55M | $2.85M | $2.15M |
| Gross Profit | $11.8M | -$305.43M | -$300.84M | -$241.62M | -$166.36M | $79.11M | -$2.85M | -$2.15M |
| Gross Margin | 76.8% | -3052.2% | -1177.6% | -17496.3% | -5492.2% | 95.7% | - | - |
| Research and Development | $261.38M | $319.09M | $330.02M | $246.35M | $295.65M | $99.86M | $70.31M | $41.03M |
| Selling, General, and Administrative | $56.71M | $80.24M | $78.58M | $69.33M | $59.75M | $38.59M | $13.74M | $8.86M |
| Other | -$3.56M | -$332.3M | -$336.44M | -$258.03M | -$157.06M | -$3.55M | $0 | -$9K |
| Total Operating Expenses | $314.54M | $67.03M | $72.16M | $57.65M | $198.34M | $134.9M | $84.05M | $49.89M |
| Operating Income (EBIT) | -$302.74M | -$372.47M | -$373M | -$299.27M | -$364.7M | -$55.8M | -$84.05M | -$49.89M |
| Operating Margin | -1971.6% | -3722.1% | -1460.1% | -21670.9% | -12040.2% | -67.5% | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $27.04M | $34.75M | $31.05M | $8.79M | $830K | $3.4M | $8.8M | $1.11M |
| Other Income (Expense) | $26.26M | $34.76M | $31.03M | $8.77M | $826K | $3.38M | $8.74M | $1.1M |
| Income Before Tax (EBT) | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M | -$52.41M | -$75.31M | -$48.78M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M | -$52.41M | -$66.5M | -$48.78M |
| Net Income Margin | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | -63.4% | - | - |
| Supplementary Data | ||||||||
| EPS | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -2.56 | -15.53 | -19.63 |
| Diluted EPS | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -2.56 | -15.53 | -19.63 |
| Weighted Average OS | 171.59M | 142.87M | 122.58M | 112.23M | 95.14M | 90.05M | 4.28M | 2.49M |
| EBITDA | -$272.92M | -$380.21M | -$374.15M | -$306.82M | -$223.08M | -$52.25M | -$81.2M | -$47.73M |
| EBITDA Margin | -1777.4% | -3799.4% | -1464.6% | -22217.4% | -7364.9% | -63.2% | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $84.02M | $124.29M | $143.74M | $151.79M | $280.12M | $447.65M | $41.95M | $421.5M |
| Short-Term Investments | $470.5M | $657.04M | $606.35M | $847.12M | $677.95M | $230.41M | $313.86M | $0 |
| Cash and Short-Term Investments | $554.52M | $781.32M | $750.09M | $998.92M | $958.07M | $678.06M | $355.82M | $421.5M |
| Accounts Receivable | $0 | $0 | $0 | $5.22M | $4.94M | $82.65M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $12.11M | $0 | $0 | $0 | $0 |
| Other Current Assets | $5.97M | $10.53M | $3.31M | $3.26M | $1.76M | $0 | $0 | $0 |
| Total Current Assets | $578.28M | $809.2M | $770.1M | $1.02B | $976.24M | $770.1M | $360.54M | $424.1M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $41.72M | $57.67M | $68.87M | $75.39M | $27.32M | $28.83M | $31.65M | $3.63M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $2.3M | $2.3M | $2.3M | $2.3M | $0 | $0 | $0 |
| Long-Term Investments | $1.34M | $0 | $2.71M | $2.58M | $0 | $0 | $0 | $878K |
| Deferred Tax Assets | $0 | $0 | $0 | -$2.58M | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $2.12M | $0 | $2.58M | $2.58M | $900K | $878K | $0 |
| Total Long-Term Assets | $43.05M | $62.09M | $73.88M | $80.27M | $32.2M | $29.73M | $32.53M | $4.51M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $621.33M | $871.3M | $843.98M | $1.1B | $1.01B | $799.83M | $393.07M | $428.61M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $7.71M | $14.1M | $9.21M | $10.58M | $8.28M | $6.35M | $6.99M | $4.71M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $7.68M | $0 | $0 | $248K | $0 | $0 | $1.86M |
| Other Current Liabilities | $463K | $2.1M | $1.91M | $26.15M | $989K | $197K | $333K | $118K |
| Total Current Liabilities | $25.58M | $50.73M | $30.27M | $63.71M | $24.32M | $13.63M | $11.99M | $6.87M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $13.21M | $32.38M | $65.26M | $3K | $537.94M | $532.67M |
| Total Long-Term Liabilities | $28.69M | $42.77M | $61.71M | $85.84M | $86.31M | $22.9M | $561.52M | $532.67M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $54.27M | $93.5M | $91.98M | $149.55M | $110.64M | $36.54M | $573.51M | $539.54M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $532.12M |
| Common Stock | $168K | $168K | $127K | $121K | $109K | $90K | $4K | $3K |
| Retained Earnings | -$2.01B | -$1.74B | -$1.4B | -$1.06B | -$768.1M | -$404.23M | -$189.48M | -$114.18M |
| Comprehensive Income & Other | $733K | -$991K | -$196K | -$10.42M | -$1.09M | $64K | $325K | -$4.65M |
| Other Stockholders' Equity | $2.58B | $2.52B | $2.15B | $2.01B | $1.67B | $1.17B | $9.04M | $3.25M |
| Total Equity | $567.06M | $777.79M | $752M | $950.22M | $897.81M | $763.29M | -$180.44M | -$110.93M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $621.33M | $871.3M | $843.98M | $1.1B | $1.01B | $799.83M | $393.07M | $428.61M |
| Supplementary Data | ||||||||
| Total Debt | $32.46M | $48.5M | $53.47M | $57.74M | $22.9M | $24.42M | $24.83M | $178K |
| Net Debt | -$51.56M | -$75.78M | -$90.27M | -$94.05M | -$257.22M | -$423.22M | -$17.12M | -$421.33M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$276.48M | -$337.71M | -$341.97M | -$290.51M | -$363.87M | -$52.41M | -$75.31M | -$48.78M |
| Depreciation & Amortization | $3.56M | $5.46M | $5.27M | $4.13M | $3.92M | $3.55M | $2.85M | $2.15M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $62.42M | $94.14M | $86.03M | $56.14M | $48.45M | $31.96M | $4.46M | $2.89M |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $5.22M | $97K | $77.79M | -$75M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | -$10.33M | $0 | $0 |
| Accounts Payable | -$11.44M | $0 | -$2.39M | $1.99M | $930K | -$410K | $3M | $1.23M |
| Other Working Capital | -$11.87M | $14.62M | -$35.28M | $9.16M | $18.62M | $571K | $1.31M | -$1.63M |
| Total Working Capital Change | -$23.31M | $14.62M | -$32.46M | $11.25M | $97.34M | -$85.17M | $4.31M | -$400K |
| Other Non-Cash Items | -$1.65M | -$25.62M | -$17.18M | -$10.49M | $139.74M | -$416K | -$2.44M | $9K |
| Net Cash from Operating | -$235.46M | -$249.11M | -$300.32M | -$229.49M | -$74.41M | -$102.49M | -$66.13M | -$44.13M |
| Investing Activities | ||||||||
| Capital Expenditures | -$410K | -$2.02M | -$4.13M | -$9.06M | -$3.47M | -$1.93M | -$8M | -$1.69M |
| Acquisitions | $0 | $0 | $0 | $179.68M | -$25.3M | -$83.6M | $0 | $7K |
| Purchases of Investments | -$122.97M | -$650.63M | -$385.54M | -$535.42M | -$980.66M | -$266.45M | -$553.52M | $0 |
| Sales of Investments | $316.18M | $611.56M | $647.3M | $355.74M | $529.92M | $350.06M | $242.47M | $0 |
| Other Investing Activities | $0 | $0 | $0 | -$179.68M | $0 | $83.6M | $20K | $7K |
| Net Cash from Investing | $192.8M | -$41.08M | $257.63M | -$188.75M | -$479.51M | $81.67M | -$319.02M | -$1.68M |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $1.6M | $265.89M | $30.28M | $284.74M | $382.21M | $425.29M | $0 | $799K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$82K |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $4.26M | $4.47M | $5.17M | $5.88M | $1.22M | $613K | $717K |
| Net Cash from Financing | $1.6M | $270.15M | $34.75M | $289.91M | $388.09M | $426.51M | $5.61M | $394.97M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$41.05M | -$20.04M | -$7.93M | -$128.32M | -$165.83M | $405.69M | -$379.55M | $349.16M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$235.46M | -$249.11M | -$300.32M | -$229.49M | -$74.41M | -$102.49M | -$66.13M | -$44.13M |
| Capital Expenditure | -$410K | -$2.02M | -$4.13M | -$9.06M | -$3.47M | -$1.93M | -$8M | -$1.69M |
| Free Cash Flow | -$235.87M | -$251.13M | -$304.44M | -$238.55M | -$77.88M | -$104.42M | -$74.14M | -$45.82M |
| Cash at Beginning | $126.41M | $146.44M | $154.37M | $282.7M | $448.52M | $42.83M | $422.38M | $73.23M |
| Cash at End | $85.35M | $126.41M | $146.44M | $154.37M | $282.7M | $448.52M | $42.83M | $422.38M |